Skip to content
Agrylin, Xagrid(anagrelide)
Agrylin, Xagrid (anagrelide) is a small molecule pharmaceutical. Anagrelide was first approved as Agrylin on 1997-03-14. It is used to treat polycythemia vera and thrombocytosis in the USA. It has been approved in Europe to treat essential thrombocythemia. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
Trade Name
FDA
EMA
Agrylin (generic drugs available since 2005-04-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Anagrelide hydrochloride
Tradename
Company
Number
Date
Products
AGRYLINTakedaN-020333 RX1997-03-14
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
agrylinNew Drug Application2020-12-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
polycythemia vera—D011087D45
thrombocytosis—D013922D75.83
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XX: Other antineoplastic agents in atc
— L01XX35: Anagrelide
HCPCS
Code
Description
G9531
Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Essential thrombocythemiaD013920D47.3—271110
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombocytosisD013922D75.83—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameANAGRELIDE
INNanagrelide
Description
Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.
Classification
Small molecule
Drug classplatelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1
Identifiers
PDB—
CAS-ID68475-42-3
RxCUI596724
ChEMBL IDCHEMBL760
ChEBI ID142290
PubChem CID2182
DrugBankDB00261
UNII IDK9X45X0051 (ChemIDplus, GSRS)
Target
Agency Approved
PDE3A
PDE3A
Organism
Homo sapiens
Gene name
PDE3A
Gene synonyms
NCBI Gene ID
5139
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Protein synonyms
cAMP phosphodiesterase, myocardial cGMP-inhibited, cGI-PDE, CGI-PDE A, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited cAMP phosphodiesterase, Cyclic GMP-inhibited phosphodiesterase A, phosphodiesterase 3A, cGMP-inhibited
Uniprot ID
Q17RD1
Mouse ortholog
Pde3a (54611)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (Q9Z0X4)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Xagrid - Shire
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 931 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
36,026 adverse events reported
View more details